# Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)

> **NCT03587376** · EARLY_PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 9 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Atabecestat

## Key facts

- **NCT ID:** NCT03587376
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-30
- **Primary completion:** 2018-08-23
- **Final completion:** 2018-08-23
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03587376

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03587376, "Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT03587376. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*